Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 +2.18%77 EV-to-FCF is 13.02 as of Aug. 02, 2026, which is 68% below its 10-year median of 40.14. GuruFocus rates SHSE:603387 with a GF Score™ of 77/100 and a GF Value™ of ¥7.57 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 417 Medical Devices & Instruments companies, Getein Biotech ranks better than 75.06% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Getein Biotech's Enterprise Value is ¥3,661 Mil.
Getein Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥281 Mil. Therefore, Getein Biotech's EV-to-FCF for today is 13.02.
The historical rank and industry rank for Getein Biotech's EV-to-FCF or its related term are showing as below:
SHSE:603387'
s EV-to-FCF Range Over the Past 10 Years
Min: 10.57 Med: 40.14 Max: 207.91
Current: 13.07
During the past 13 years, the highest EV-to-FCF of Getein Biotech was 207.91. The lowest was 10.57. And the median was 40.14.
SHSE:603387's EV-to-FCF is ranked better than 75.06% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.52
vs SHSE:603387: 13.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Getein Biotech's PE Ratio (TTM) for today is calculated as:
Getein Biotech's share price for today is ¥8.90.
Getein Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Getein Biotech EV-to-FCF Related Terms
Getein Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Getein Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603387 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Getein Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Getein Biotech's EV-to-FCF falls into.
Getein Biotech's current Enterprise Value is ¥3,661 Mil.
Getein Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥281 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getein Biotech (SHSE:603387) has a EV-to-FCF of 13.02 as of Aug. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Getein Biotech and its competitors. This is 68% below median its historical median of 40.14. Over the past decade, Getein Biotech's EV-to-FCF has ranged from 10.57 to 207.91. According to the industry distribution chart, Getein Biotech ranks #104 out of 417 companies in the Medical Devices & Instruments industry, placing it in the top 24.9%.
Is Getein Biotech's EV-to-FCF too high?
Getein Biotech's current EV-to-FCF of 13.02 is 68% below median its 10-year median of 40.14. Over the past 10 years, this metric has ranged from a low of 10.57 to a high of 207.91. The Medical Devices & Instruments industry median EV-to-FCF is 23.52. Getein Biotech's value of 13.02 is 44.6% below this industry median. Based on the distribution chart, Getein Biotech ranks #104 out of 417 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getein Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #104 out of 417 companies for EV-to-FCF. This places Getein Biotech in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 23.52. Getein Biotech's value of 13.02 is 44.6% below this benchmark. Historically, Getein Biotech's own EV-to-FCF has ranged from 10.57 to 207.91 over the past decade. While the company's 10-year median is 40.14 vs. the industry median of 23.52, Getein Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.52, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getein Biotech's current EV-to-FCF of 13.02 is 44.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Getein Biotech and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getein Biotech's current EV-to-FCF is 13.02, which is 68% below median its own 10-year median of 40.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.57, compared to a current price of ¥8.90 — trading 17.6% above its estimated fair value. The current EV-to-FCF is 13.02, which is 68% below median its 10-year median of 40.14 and 44.6% below the Medical Devices & Instruments industry median of 23.52. Getein Biotech's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current EV-to-FCF is 13.02 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥8.90 is trading 17.6% above its estimated GF Value™ of ¥7.57.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
EV-to-FCF: 13.02 (68% below median its 10-year median of 40.14)
GF Value™: ¥7.57 vs. price of ¥8.90 (17.6% above fair value)
Industry Position: 44.6% below the Medical Devices & Instruments median (#104 of 417)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
77GF Score
Get the complete analysis for SHSE:603387
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
